ECO 2026 shifted obesity care away from BMI and weight loss alone, framing it instead as a systemic illness requiring organ-level intervention across comorbidities.
Madrigal and Novo Nordisk used the meeting to spotlight metabolic dysfunction-associated steatohepatitis, arguing obesity and diabetes clinics are key sites for earlier detection before liver disease advances.
Madrigal promoted a stepwise screening pathway using FIB-4 first, then ELF or VCTE, while warning VCTE loses accuracy as BMI rises and blood-based ELF may fit obesity clinics better.
Novo Nordisk cited SELECT, STEP-HFpEF and ESSENCE data to argue obesity treatment should target cardiovascular, hepatic and functional outcomes through coordinated care across specialties.
GlobalData projects diagnosed prevalent MASH cases across all ages will reach about 229 million by 2032, underscoring the broader push for earlier, multidisciplinary obesity management.
Can healthcare systems afford mass MASH screening and lifelong drug therapy for millions of patients with obesity?
As new MASH therapies emerge, will combination treatments or a single 'super-drug' dominate the future $33 billion market?
Is the 'holistic' obesity care model truly for patients, or is it a new frontier for pharmaceutical profits?
The Global Surge of Obesity and MASH: Redefining Disease, Escalating Burden, and the Urgent Need for Systemic Action
Overview
The 33rd European Congress on Obesity (ECO 2026) marked a turning point by redefining obesity as a complex, chronic, and systemic illness that affects multiple organs, not just body weight. This new understanding highlights the strong link between obesity and serious conditions like Metabolic Dysfunction-Associated Steatohepatitis (MASH), which can lead to liver failure. As a result, treatment strategies are shifting from simply reducing BMI to targeting specific organs and requiring multidisciplinary care. This approach aims to provide more effective therapies and improve long-term outcomes, paving the way for better strategies in fighting obesity and its complications.